E2F1: A new role in the DNA damage response.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.Oncotarget · 2016
   Trial
2. ATM-dependent E2F1 accumulation in the nucleolus is an indicator of ribosomal stress in early response to DNA damage.Cell cycle (Georgetown, Tex.) · 2014
   Article
3. Retinoic acid-related orphan receptor-α is induced in the setting of DNA damage and promotes pulmonary emphysema.American journal of respiratory and critical care medicine · 2012
   Article

Corrections and comments

• Comment on
  E2F1 promotes the recruitment of DNA repair factors to sites of DNA double-strand breaks.2011

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as